Trial Profile
A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary) ; Triptorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRIMORDIUM
- Sponsors Janssen-Cilag
- 26 Mar 2024 Planned End Date changed from 28 Jan 2030 to 27 Aug 2029.
- 26 Mar 2024 Planned primary completion date changed from 28 Jan 2030 to 27 Aug 2029.
- 27 Jan 2024 Baseline characteristics (n=198) were presented at the 2024 Genitourinary Cancers Symposium.